Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian B McDermott

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Nature Communications|February 9, 2020
Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responsesSeyhan Boyoglu-Barnum, Geoffrey B Hutchinson, Jeffrey C Boyington, et al.
Structure (London, England : 1993)|August 15, 2025
The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibodyReda Rawi, Nicholas C Morano, Crystal Sao-Fong Cheung, et al.
Nature Chemical Biology|August 22, 2017
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529Marie Pancera, Yen-Ting Lai, Tatsiana Bylund, et al.
Immunity|October 28, 2022
Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibitionWei-Hung Chen, JungHyun Kim, Wei Bu, et al.
Nature Communications|November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosaMaria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Journal of Virology|February 16, 2018
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph NodesSinthujan Jegaskanda, Rosemarie D Mason, Sarah F Andrews, et al.
Journal of Clinical Pharmacology|June 9, 2025
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIVYunda Huang, Lily Zhang, Maria P Lemos, et al.
JCI Insight|March 15, 2021
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
The Lancet. HIV|March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trialSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
Vaccine|November 24, 2021
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceKai Wu, Angela Choi, Matthew Koch, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Nature Communications|February 9, 2020
Glycan repositioning of influenza hemagglutinin stem facilitates the elicitation of protective cross-group antibody responsesSeyhan Boyoglu-Barnum, Geoffrey B Hutchinson, Jeffrey C Boyington, et al.
Structure (London, England : 1993)|August 15, 2025
The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibodyReda Rawi, Nicholas C Morano, Crystal Sao-Fong Cheung, et al.
Nature Chemical Biology|August 22, 2017
Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529Marie Pancera, Yen-Ting Lai, Tatsiana Bylund, et al.
Immunity|October 28, 2022
Epstein-Barr virus gH/gL has multiple sites of vulnerability for virus neutralization and fusion inhibitionWei-Hung Chen, JungHyun Kim, Wei Bu, et al.
Nature Communications|November 28, 2024
Enhanced and sustained biodistribution of HIV-1 neutralizing antibody VRC01LS in human genital and rectal mucosaMaria P Lemos, Rena D Astronomo, Yunda Huang, et al.
Journal of Virology|February 16, 2018
Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph NodesSinthujan Jegaskanda, Rosemarie D Mason, Sarah F Andrews, et al.
Journal of Clinical Pharmacology|June 9, 2025
Pharmacokinetics Analysis of Serum and Rectal Tissue Concentrations of a Pair of Anti-HIV Monoclonal Antibodies, VRC01 and VRC01LS, in Adults without HIVYunda Huang, Lily Zhang, Maria P Lemos, et al.
JCI Insight|March 15, 2021
A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2Abdelilah Majdoubi, Christina Michalski, Sarah E O'Connell, et al.
The Lancet. HIV|March 31, 2023
Safety and pharmacokinetics of escalating doses of neutralising monoclonal antibody CAP256V2LS administered with and without VRC07-523LS in HIV-negative women in South Africa (CAPRISA 012B): a phase 1, dose-escalation, randomised controlled trialSharana Mahomed, Nigel Garrett, Edmund V Capparelli, et al.
Vaccine|November 24, 2021
Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in miceKai Wu, Angela Choi, Matthew Koch, et al.
Pageof 18